Marijuana, Law Enforcement and Young New Yorkers | the New School
Marijuana, Law Enforcement and Young New Yorkers | The New School – Study non-profit management, urban and environmental policy, human resources, and international affairs at the Milano School of International Affairs, Management, and Urban Policy, a part of The New School in New York City. | www.newschool.edu According to the New York Division of Criminal Justice Services, 70 percent of the 50383 arrests for possession of marijuana in New York City in 2010 were of young people under thirty, and 86 percent of those arrested were black and Latino. The debate on the classification of marijuana possession as a crime is heating up nationwide, even as the number of arrests in New York has risen. Many substance abuse professionals, public officials, and community anti-crime activists support a drug enforcement strategy that includes “broken windows” policing and drug treatment. Others question whether this is worth the cost, including the criminal convictions that can damage young people’s prospects for education and jobs. Is it time for change, or not? THE NEW SCHOOL | www.newschool.edu Panelists Dan Donovan, Staten Island District Attorney; Oma S. Holloway, director of career services, The Door – A Center of Alternatives; Noah Kass, LMSW and clinical director, Realization Center, Inc; Jenay Nurse, staff attorney, Bronx Defenders; Gabriel Sayegh, New York State director, Drug Policy Alliance. Moderated by Cindy Rodriguez, WNYC This event is supported by the Sirus Fund and the Milano Foundation. Presented by the Center for New York City Affairs …
AstraZeneca v European Commission, Case c-457/10 P
Filed under: drug abuse treatment cost analysis program
On 6 December 2012, the European Court of Justice (the “ECJ”) upheld the judgment of the General Court (“GC”), which found that AstraZeneca (“AZ”) abused its dominant position on the market for proton pump inhibitors (“PPIs”) by misleading patent …
Read more on Lexology (registration)
Novartis drug Signifor(R) gains FDA approval as the first medication to treat …
Filed under: drug abuse treatment cost analysis program
Basel, December 14, 2012 – Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor ® (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or …
Read more on Reuters